Shandong Lukang Pharmaceutical Co.,Ltd.

600789

CNE000000P61

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
7.49 ^CNY	+0.54%		-3.85%	+4.90%

May. 29	China Approves Lukang Pharma's Anti-Asthma Injection	MT
Apr. 23	Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shandong Lukang Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year 2017

January 24, 2018

Shandong Lukang Pharmaceutical Co.,Ltd. provided earnings guidance for the year 2017. For the year, the company expected the net profit owned by shareholders of the listed company in 2017 will increase by between RMB 85 million and RMB 90 million, with an increase of between 292.10% and 309.28% compared with the same period of the year before.

Latest news about Shandong Lukang Pharmaceutical Co.,Ltd.

China Approves Lukang Pharma's Anti-Asthma Injection	May. 29	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Lukang Pharmaceutical Gets Nod to Produce Parkinson's Disease Drug	Jan. 25	MT
Lukang Pharmaceutical's Piperacillin Sodium, Tazobactam Sodium Injection Passes Regulatory Evaluation	Nov. 13	MT
Lukang Pharmaceutical's Ampicillin Sodium and Sulbactam Sodium Pass Regulatory Evaluation	Nov. 02	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Lukang Pharmaceutical's Ornidazole Tablets Passes Regulatory Evaluation	23-09-18	MT
Shandong Lukang Pharmaceutical Co.,Ltd.(XSSC:600789) added to S&P Global BMI Index	23-09-18	CI
Lukang Pharma Generic Hypertension Drug Passes Regulatory Evaluation	23-09-08	MT
Lukang Pharmaceutical's Cefaclor Granules Passes Chinese Drug Regulator's Evaluation	23-09-06	MT
Lukang Pharmaceutical's Cefixime Tablets Passes Regulator's Evaluation	23-08-18	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Lukang Pharmaceutical's Cefminox Sodium for Injection Passes Regulatory Evaluation	23-07-25	MT
Lukang Pharmaceutical's Cefaclor Capsules Passes Regulatory Evaluation	23-07-12	MT
Lukang Pharma's Cefazolin Sodium for Injection Passes Drug Regulator's Evaluation	23-05-18	MT
Lukang Pharma's Ampicillin Sodium for Injection Passes Regulatory Evaluation	23-05-09	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-18	CI
Lukang Pharma Gets Nod to Market Anti-Arthritis Drug Ingredient	23-02-23	MT
Lukang Pharma’s Benzyl Alcohol Wins Marketing Approval in China	23-02-09	MT
Shandong Lukang Pharmaceutical Raising 1.2 Billion Yuan to Fund Expansion Plans	23-01-03	MT
Lukang Pharma Gets Regulatory Nod for Anti-Pneumonia Drug	22-12-20	MT
Lukang Pharmaceutical Gets Approval for Diabetes Treatment Tablet	22-11-16	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Shandong Lukang Pharmaceutical Co.,Ltd. acquired remaining 60% stake in Shandong Lukang Zhonghe Environmental Protection Technology Co., Ltd. from Hualu Holdings Co., Ltd	22-08-25	CI

Chart Shandong Lukang Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shandong Lukang Pharmaceutical Co.,Ltd.

More charts

Company Profile

Shandong Lukang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The Company's primary products include pharmaceutical preparation products, semi-synthetic antibiotic raw materials, veterinary antibiotics and antibiotic raw materials and others. The Company is also involved in the production and distribution of pharmaceutical intermediates. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANDONG LUKANG PHARMACEUTICAL CO.,LTD.	+4.90%	926M
ELI LILLY AND COMPANY	+45.82%	765B
NOVO NORDISK A/S	+40.95%	632B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
NOVARTIS AG	+11.88%	216B
ROCHE HOLDING AG	-0.78%	219B
AMGEN INC.	+5.90%	164B

Other Pharmaceuticals